Comparative Real-World Efficacy of Anti-Vascular Endothelial Growth Factor Agents in Neovascular Age-Related Macular Degeneration: A Multicenter Retrospective Study.

Ophthalmologica · 2026 · PMC12845526 · PMID 41417677

Europe PMC DOI

hedged sentences

0.0590

closest p · 1.2× alpha

0.0940

boldest claim

The sentences

just short of significancep = 0.059so close (0.05 < p ≤ 0.1)

It showed the largest mean VA gain, just short of significance on multivariable analysis ( p = 0.059).

also in 57 other papers

failed to reach statistical significancep = 0.075so close (0.05 < p ≤ 0.1)

Bevacizumab responders received the highest total number of injections, whereas aflibercept required the fewest, although this trend failed to reach statistical significance ( p = 0.075).

also in 6,035 other papers

a nonsignificant trendp = 0.094so close (0.05 < p ≤ 0.1)

Compared with bevacizumab, aflibercept extended final treatment intervals by 2.14 weeks ( p < 0.001) and reduced the total number of injections by 2.35 ( p = 0.001), while ranibizumab showed a nonsignificant trend toward longer final intervals (+0.84 weeks; p = 0.094) and did not significantly reduce injection count (−0.51; p = 0.299).

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.